Giant Gastrointestinal Stromal Tumor with Remarkable Preoperative Response to Imatinib Mesylate

Abstract

Get full access to this article

View all access options for this article.

References

Eisenberg

B.L.

, Judson

Surgery and imatinib in the management of GIST: emerging approaches to adjuvant and neo-adjuvant therapy.

Ann Surg Oncol 2004; 11: 465–75.

Jamali

F.R.

, Darwiche

S.S.

, El-Kinge

Disease progression following imatinib failure in gastrointestinal stromal tumors: role of surgical therapy.

Oncologist 2007; 12: 438–42.

Eisenber

B.L.

, Harris

, Blanke

C.D.

Phase II trial of neoadjuvant/adjuvant imatinib mesylate for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumor: early results of RTOG 0132/ACRIN6665.

J Surg Oncol 2009; 99: 42–7.

Demetri

, von Mehren

, Blanke

Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors.

N Engl J Med 2002; 347: 472–80.